{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:01:34Z","timestamp":1784581294309,"version":"3.55.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"DOI":"10.1007\/s11910-026-01503-4","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:26:05Z","timestamp":1784532365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Postoperative Seizure Prophylaxis in Intracranial Tumors: Evaluating the Role of Anti-Seizure Medication in Seizure-Na\u00efve Patients"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-675X","authenticated-orcid":false,"given":"Nitish","family":"Seenarine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2908-2586","authenticated-orcid":false,"given":"Samuel","family":"Latzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mittelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Zhigin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Hirowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0032-5310","authenticated-orcid":false,"given":"Shoaib","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heustein","family":"Sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3047-945X","authenticated-orcid":false,"given":"Randy S.","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"1503_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos199","author":"R Rud\u00e0","year":"2012","unstructured":"Rud\u00e0 R, Bello L, Duffau H, Soffietti R. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol. 2012. https:\/\/doi.org\/10.1093\/neuonc\/nos199.","journal-title":"Neuro Oncol"},{"key":"1503_CR2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/neuros\/nyw062","volume":"80","author":"HH Dasenbrock","year":"2017","unstructured":"Dasenbrock HH, Yan SC, Smith TR, et al. Readmission After Craniotomy for Tumor: A National Surgical Quality Improvement Program Analysis. Neurosurgery. 2017;80:551\u201362. https:\/\/doi.org\/10.1093\/neuros\/nyw062.","journal-title":"Neurosurgery"},{"key":"1503_CR3","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3171\/2014.1.JNS131264","volume":"120","author":"LP Marcus","year":"2014","unstructured":"Marcus LP, McCutcheon BA, Noorbakhsh A, et al. Incidence and predictors of 30-day readmission for patients discharged home after craniotomy for malignant supratentorial tumors in California (1995\u20132010). J Neurosurg. 2014;120:1201\u201311. https:\/\/doi.org\/10.3171\/2014.1.JNS131264.","journal-title":"J Neurosurg"},{"key":"1503_CR4","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12883-022-02762-7","volume":"22","author":"E Konrath","year":"2022","unstructured":"Konrath E, Marhold F, Kindler W, et al. Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning. BMC Neurol. 2022;22:250. https:\/\/doi.org\/10.1186\/s12883-022-02762-7.","journal-title":"BMC Neurol"},{"key":"1503_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00701-025-06486-8","volume":"167","author":"SEA van Maanen","year":"2025","unstructured":"van Maanen SEA, Zijlmans MJM, van Eijsden P, van der Salm SMA. Do acute postoperative seizures predict epilepsy surgery outcome? a scoping review. Acta Neurochir (Wien). 2025;167:72. https:\/\/doi.org\/10.1007\/s00701-025-06486-8.","journal-title":"Acta Neurochir (Wien)"},{"key":"1503_CR6","doi-asserted-by":"publisher","unstructured":"Tortuyaux R, Wallet F, Derambure P, Nseir S. Bacterial Aspiration Pneumonia in Generalized Convulsive Status Epilepticus: Incidence, Associated Factors and Outcome. J Clin Med. 2022;11. https:\/\/doi.org\/10.3390\/jcm11226673.","DOI":"10.3390\/jcm11226673"},{"key":"1503_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18126390","author":"S Krajewski","year":"2021","unstructured":"Krajewski S, Wojcik M, Harat M, Furtak J. Influence of epilepsy on the quality of life of patients with brain tumors. Int J Environ Res Public Health. 2021. https:\/\/doi.org\/10.3390\/ijerph18126390.","journal-title":"Int J Environ Res Public Health"},{"key":"1503_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/nop\/npae119","volume":"12","author":"MWL Mondia","year":"2025","unstructured":"Mondia MWL, Avila EK, Wefel JS, et al. Brain tumors and fitness to drive: A review and multi-disciplinary approach. Neurooncol Pract. 2025;12:183\u201396. https:\/\/doi.org\/10.1093\/nop\/npae119.","journal-title":"Neurooncol Pract"},{"key":"1503_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.seizure.2014.02.010","volume":"23","author":"HM Greiner","year":"2014","unstructured":"Greiner HM, Horn PS, Arya R, et al. Acute postoperative seizures and long-term outcome following pediatric epilepsy surgery. Seizure. 2014;23:483\u20136. https:\/\/doi.org\/10.1016\/j.seizure.2014.02.010.","journal-title":"Seizure"},{"key":"1503_CR10","doi-asserted-by":"publisher","unstructured":"Maanen SEAv, Zijlmans MJM, Eijsden Pv. Salm SMAvd: Do acute postoperative seizures predict epilepsy surgery outcome? a scoping review. Acta Neurochir 2025 Mar 13, 167. https:\/\/doi.org\/10.1007\/s00701-025-06486-8","DOI":"10.1007\/s00701-025-06486-8"},{"key":"1503_CR11","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.3171\/2022.1.FOCUS21751","volume":"52","author":"MC Jin","year":"2022","unstructured":"Jin MC, Parker JJ, Prolo LM, et al. An integrated risk model stratifying seizure risk following brain tumor resection among seizure-naive patients without antiepileptic prophylaxis. Neurosurg Focus. 2022;52:E3. https:\/\/doi.org\/10.3171\/2022.1.FOCUS21751.","journal-title":"Neurosurg Focus"},{"key":"1503_CR12","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/neuonc\/noab152","volume":"23","author":"T Walbert","year":"2021","unstructured":"Walbert T, Harrison RA, Schiff D, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 2021;23:1835\u201344. https:\/\/doi.org\/10.1093\/neuonc\/noab152.","journal-title":"Neuro Oncol"},{"key":"1503_CR13","doi-asserted-by":"publisher","first-page":"E195","DOI":"10.1093\/neuros\/nyy545","volume":"84","author":"CC Chen","year":"2019","unstructured":"Chen CC, Rennert RC, Olson JJ. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Prophylactic Anticonvulsants in the Treatment of Adults with Metastatic Brain Tumors. Neurosurgery. 2019;84:E195\u20137. https:\/\/doi.org\/10.1093\/neuros\/nyy545.","journal-title":"Neurosurgery"},{"key":"1503_CR14","doi-asserted-by":"publisher","unstructured":"CY W, YT PCH, KC C, HW L. Y: Effects of mirror therapy on motor and sensory recovery in chronic stroke: a randomized controlled trial - PubMed. Archives Phys Med rehabilitation 2013 Jun, 94. https:\/\/doi.org\/10.1016\/j.apmr.2013.02.007","DOI":"10.1016\/j.apmr.2013.02.007"},{"key":"1503_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/jnnp-2018-319609","volume":"04\u201311","author":"C Mirian","year":"2019","unstructured":"Mirian C, Pedersen MM, Sabers A, Mathiesen T. Antiepileptic drugs as prophylaxis for de novo brain tumour-related epilepsy after craniotomy: a systematic review and meta-analysis of harm and benefits. J Neurol Neurosurg Psychiatry. 2019;04\u201311:90. https:\/\/doi.org\/10.1136\/jnnp-2018-319609.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1503_CR16","doi-asserted-by":"publisher","unstructured":"Dewan MC, White-Dzuro GA, Brinson PR, et al. The Influence of Perioperative Seizure Prophylaxis on Seizure Rate and Hospital Quality Metrics Following Glioma Resection. Neurosurgery. 2017 Feb;1:80. https:\/\/doi.org\/10.1093\/neuros\/nyw106.","DOI":"10.1093\/neuros\/nyw106"},{"key":"1503_CR17","doi-asserted-by":"publisher","unstructured":"AK VC. A systematic review of perioperative seizure prophylaxis during brain tumor resection: the case for a multicenter randomized clinical trial - PubMed. NeuroSurg Focus. 2017 Nov;43. https:\/\/doi.org\/10.3171\/2017.8.FOCUS17442.","DOI":"10.3171\/2017.8.FOCUS17442"},{"key":"1503_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13223415","author":"S Batista","year":"2023","unstructured":"Batista S, Bertani R, Palavani LB, et al. Postoperative seizure prophylaxis in meningioma resection: a systematic review and meta-analysis. Diagnostics (Basel). 2023. https:\/\/doi.org\/10.3390\/diagnostics13223415.","journal-title":"Diagnostics (Basel)"},{"key":"1503_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/noajnl\/vdae127","volume":"01\/01","author":"AS Youshani","year":"2024","unstructured":"Youshani AS, Heal C, Lee JX, et al. Glioma-related epilepsy following low-grade glioma surgery. Neuro-Oncology Adv. 2024;01\/01:6. https:\/\/doi.org\/10.1093\/noajnl\/vdae127.","journal-title":"Neuro-Oncology Adv"},{"key":"1503_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.905976","author":"RE Ahmed","year":"2022","unstructured":"Ahmed RE, Tang H, Asemota A, Huang L, Boling W, Bannout F. Meningioma related epilepsy- pathophysiology, pre\/postoperative seizures predicators and treatment. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.905976.","journal-title":"Front Oncol"},{"key":"1503_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030450","author":"P Baumgarten","year":"2021","unstructured":"Baumgarten P, Sarlak M, Monden D, et al. Early and late postoperative seizures in meningioma patients and prediction by a recent scoring system. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13030450.","journal-title":"Cancers"},{"key":"1503_CR22","doi-asserted-by":"publisher","unstructured":"PD, D-L, S O-C, JJ GB, E C-D. : Seizure prophylaxis in meningiomas: A systematic review and meta-analysis - PubMed. Neurologia 09\/04\/2020, 38. https:\/\/doi.org\/10.1016\/j.nrl.2020.06.014","DOI":"10.1016\/j.nrl.2020.06.014"},{"key":"1503_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/brain\/awt345","volume":"137","author":"J Pallud","year":"2014","unstructured":"Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain. 2014;137:449\u201362. https:\/\/doi.org\/10.1093\/brain\/awt345.","journal-title":"Brain"},{"key":"1503_CR24","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(23)01054-1","volume":"402","author":"MJ van den Bent","year":"2023","unstructured":"van den Bent MJ, Geurts M, French PJ, et al. Primary brain tumours in adults. Lancet. 2023;402:1564\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(23)01054-1.","journal-title":"Lancet"},{"key":"1503_CR25","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/neuonc\/noac003","volume":"24","author":"A Mortazavi","year":"2022","unstructured":"Mortazavi A, Fayed I, Bachani M, et al. IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation. Neuro Oncol. 2022;24:1423\u201335. https:\/\/doi.org\/10.1093\/neuonc\/noac003.","journal-title":"Neuro Oncol"},{"key":"1503_CR26","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1212\/WNL.0000000000003911","volume":"88","author":"H Chen","year":"2017","unstructured":"Chen H, Judkins J, Thomas C, et al. Mutant IDH1 and seizures in patients with glioma. Neurology. 2017;88:1805\u201313. https:\/\/doi.org\/10.1212\/WNL.0000000000003911.","journal-title":"Neurology"},{"key":"1503_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/GJMJ1815","volume":"30","author":"MD Jenkinson","year":"2026","unstructured":"Jenkinson MD, Bulbeck H, Carruthers J, et al. Seizure prophylaxis in glioma surgery: a synopsis from the SPRING RCT. Health Technol Assess. 2026;30:1\u201340. https:\/\/doi.org\/10.3310\/GJMJ1815.","journal-title":"Health Technol Assess"},{"key":"1503_CR28","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S1470-2045(25)00472-3","volume":"26","author":"TF Cloughesy","year":"2025","unstructured":"Cloughesy TF, van den Bent MJ, Touat M, et al. Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2025;26:1665\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(25)00472-3.","journal-title":"Lancet Oncol"},{"key":"1503_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11864-024-01182-8","volume":"25","author":"HB Newton","year":"2024","unstructured":"Newton HB, Wojkowski J. Antiepileptic Strategies for Patients with Primary and Metastatic Brain Tumors. Curr Treat Options Oncol. 2024;25:389\u2013403. https:\/\/doi.org\/10.1007\/s11864-024-01182-8.","journal-title":"Curr Treat Options Oncol"},{"key":"1503_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04787-z","author":"RG Rilinger","year":"2024","unstructured":"Rilinger RG, Guo L, Sharma A, et al. Tumor-related epilepsy in high-grade glioma: a large series survival analysis. J Neurooncol. 2024. https:\/\/doi.org\/10.1007\/s11060-024-04787-z.","journal-title":"J Neurooncol"},{"key":"1503_CR31","doi-asserted-by":"publisher","unstructured":"AS W, VT T. D S, : A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors - PubMed. J Neurosurg 2013 Apr, 118. https:\/\/doi.org\/10.3171\/2012.12.JNS111970","DOI":"10.3171\/2012.12.JNS111970"},{"key":"1503_CR32","doi-asserted-by":"publisher","unstructured":"Bruin MEd M, PBvd, Dirven L, Taphoorn MJB, Koekkoek JAF. Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review. Neuro-Oncology Pract. 2021 May;28:8. https:\/\/doi.org\/10.1093\/nop\/npab030.","DOI":"10.1093\/nop\/npab030"},{"key":"1503_CR33","doi-asserted-by":"publisher","first-page":"107033","DOI":"10.1016\/j.eplepsyres.2022.107033","volume":"187","author":"C Audrey","year":"2022","unstructured":"Audrey C, Lim KS, Ahmad Zaki R, et al. Prevalence of seizures in brain tumor: A meta-analysis. Epilepsy Res. 2022;187:107033. https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.107033.","journal-title":"Epilepsy Res"},{"key":"1503_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1528-1167.2011.03269.x","volume":"53","author":"DJ Englot","year":"2012","unstructured":"Englot DJ, Berger MS, Barbaro NM, Chang EF. Factors associated with seizure freedom in the surgical resection of glioneuronal tumors. Epilepsia. 2012;53:51\u20137. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03269.x.","journal-title":"Epilepsia"},{"key":"1503_CR35","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1056\/NEJMoa1703784","volume":"377","author":"I Blumcke","year":"2017","unstructured":"Blumcke I, Spreafico R, Haaker G, et al. Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. N Engl J Med. 2017;377:1648\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1703784.","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"1503_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1528-1167.2007.01291.x","volume":"48","author":"V Schick","year":"2007","unstructured":"Schick V, Majores M, Koch A, et al. Alterations of phosphatidylinositol 3-kinase pathway components in epilepsy-associated glioneuronal lesions. Epilepsia. 2007;48(Suppl 5):65\u201373. https:\/\/doi.org\/10.1111\/j.1528-1167.2007.01291.x.","journal-title":"Epilepsia"},{"key":"1503_CR37","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1474-4422(21)00265-9","volume":"20","author":"I Blumcke","year":"2021","unstructured":"Blumcke I, Budday S, Poduri A, Lal D, Kobow K, Baulac S. Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours. Lancet Neurol. 2021;20:943\u201355. https:\/\/doi.org\/10.1016\/S1474-4422(21)00265-9.","journal-title":"Lancet Neurol"},{"key":"1503_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npae103","author":"JCC Scheepens","year":"2024","unstructured":"Scheepens JCC, van der Meer PB, Dirven L, Vos MJ, Taphoorn MJB, Koekkoek JAF. Seizure outcomes in patients with brain metastases and epilepsy: a systematic review on the efficacy of antitumor treatment and antiseizure medication. Neuro-Oncology Pract. 2024. https:\/\/doi.org\/10.1093\/nop\/npae103.","journal-title":"Neuro-Oncology Pract"},{"key":"1503_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz172","author":"F Wolpert","year":"2019","unstructured":"Wolpert F, Lareida A, Terziev R, et al. Risk factors for the development of epilepsy in patients with brain metastases. Neuro-oncol. 2019. https:\/\/doi.org\/10.1093\/neuonc\/noz172.","journal-title":"Neuro-oncol"},{"key":"1503_CR40","doi-asserted-by":"publisher","DOI":"10.4103\/1793-5482.125658","author":"S Gokhale","year":"2013","unstructured":"Gokhale S, Khan SA, Agrawal A, Friedman AH, McDonagh DL. Levetiracetam seizure prophylaxis in craniotomy patients at high risk for postoperative seizures. Asian J Neurosurg. 2013. https:\/\/doi.org\/10.4103\/1793-5482.125658.","journal-title":"Asian J Neurosurg"},{"key":"1503_CR41","doi-asserted-by":"publisher","first-page":"e1237","DOI":"10.1212\/WNL.0000000000011459","volume":"96","author":"N Lamba","year":"2021","unstructured":"Lamba N, Catalano PJ, Cagney DN, et al. Seizures Among Patients With Brain Metastases: A Population- and Institutional-Level Analysis. Neurology. 2021;96:e1237\u201350. https:\/\/doi.org\/10.1212\/WNL.0000000000011459.","journal-title":"Neurology"},{"key":"1503_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11060-012-0802-y","volume":"108","author":"SA Goldlust","year":"2012","unstructured":"Goldlust SA, Hsu M, Lassman AB, Panageas KS, Avila EK. Seizure prophylaxis and melanoma brain metastases. J Neurooncol. 2012;108:109\u201314. https:\/\/doi.org\/10.1007\/s11060-012-0802-y.","journal-title":"J Neurooncol"},{"key":"1503_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.nec.2020.06.008","author":"MA Monsour","year":"2020","unstructured":"Monsour MA, Kelly PD, Chambless LB. Antiepileptic drugs in the management of cerebral metastases. Neurosurg Clin N Am. 2020. https:\/\/doi.org\/10.1016\/j.nec.2020.06.008.","journal-title":"Neurosurg Clin N Am"},{"key":"1503_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npaf001","author":"EJ Vaios","year":"2025","unstructured":"Vaios EJ, Maingi S, Batich K, et al. Seizure risk factors and management approaches in patients with brain metastases. Neuro-Oncology Pract. 2025. https:\/\/doi.org\/10.1093\/nop\/npaf001.","journal-title":"Neuro-Oncology Pract"},{"key":"1503_CR45","doi-asserted-by":"publisher","unstructured":"Ersoy TF, Ridwan S, Grote A et al. Early postoperative seizures (EPS) in patients undergoing brain tumour surgery. Sci Rep 2020 10:1. 2020-08-13, 10. https:\/\/doi.org\/10.1038\/s41598-020-70754-z","DOI":"10.1038\/s41598-020-70754-z"},{"key":"1503_CR46","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1054\/jocn.2000.0825","volume":"8","author":"SL Hwang","year":"2001","unstructured":"Hwang SL, Lieu AS, Kuo TH, et al. Preoperative and postoperative seizures in patients with astrocytic tumours: analysis of incidence and influencing factors. J Clin Neurosci. 2001;8:426\u20139. https:\/\/doi.org\/10.1054\/jocn.2000.0825.","journal-title":"J Clin Neurosci"},{"key":"1503_CR47","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00701-021-05067-9","volume":"164","author":"RA Morshed","year":"2022","unstructured":"Morshed RA, Young JS, Gogos AJ, et al. Reducing complication rates for repeat craniotomies in glioma patients: a single-surgeon experience and comparison with the literature. Acta Neurochir (Wien). 2022;164:405\u201317. https:\/\/doi.org\/10.1007\/s00701-021-05067-9.","journal-title":"Acta Neurochir (Wien)"},{"key":"1503_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11060-018-03058-y","volume":"142","author":"CM Zattra","year":"2019","unstructured":"Zattra CM, Zhang DY, Broggi M, et al. Repeated craniotomies for intracranial tumors: is the risk increased? Pooled analysis of two prospective, institutional registries of complications and outcomes. J Neurooncol. 2019;142:49\u201357. https:\/\/doi.org\/10.1007\/s11060-018-03058-y.","journal-title":"J Neurooncol"},{"key":"1503_CR49","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3171\/jns.1983.58.5.0672","volume":"58","author":"JB North","year":"1983","unstructured":"North JB, Penhall RK, Hanieh A, Frewin DB, Taylor WB. Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg. 1983;58:672\u20137. https:\/\/doi.org\/10.3171\/jns.1983.58.5.0672.","journal-title":"J Neurosurg"},{"key":"1503_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/BF01420191","volume":"103","author":"S Franceschetti","year":"1990","unstructured":"Franceschetti S, Binelli S, Casazza M, et al. Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir (Wien). 1990;103:47\u201351. https:\/\/doi.org\/10.1007\/BF01420191.","journal-title":"Acta Neurochir (Wien)"},{"key":"1503_CR51","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1017\/s0317167100053361","volume":"30","author":"PA Forsyth","year":"2003","unstructured":"Forsyth PA, Weaver S, Fulton D, et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci. 2003;30:106\u201312. https:\/\/doi.org\/10.1017\/s0317167100053361.","journal-title":"Can J Neurol Sci"},{"key":"1503_CR52","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3171\/2012.12.JNS111970","volume":"118","author":"AS Wu","year":"2013","unstructured":"Wu AS, Trinh VT, Suki D, et al. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg. 2013;118:873\u201383. https:\/\/doi.org\/10.3171\/2012.12.JNS111970.","journal-title":"J Neurosurg"},{"key":"1503_CR53","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.4065\/79.12.1489","volume":"79","author":"JI Sirven","year":"2004","unstructured":"Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004;79:1489\u201394. https:\/\/doi.org\/10.4065\/79.12.1489.","journal-title":"Mayo Clin Proc"},{"key":"1503_CR54","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.3171\/2017.8.FOCUS17442","volume":"43","author":"V Chandra","year":"2017","unstructured":"Chandra V, Rock AK, Opalak C, et al. A systematic review of perioperative seizure prophylaxis during brain tumor resection: the case for a multicenter randomized clinical trial. Neurosurg Focus. 2017;43:E18. https:\/\/doi.org\/10.3171\/2017.8.FOCUS17442.","journal-title":"Neurosurg Focus"},{"key":"1503_CR55","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3171\/2017.10.JNS172236","volume":"130","author":"EF Joiner","year":"2019","unstructured":"Joiner EF, Youngerman BE, Hudson TS, et al. Effectiveness of perioperative antiepileptic drug prophylaxis for early and late seizures following oncologic neurosurgery: a meta-analysis. J Neurosurg. 2019;130:1274\u201382. https:\/\/doi.org\/10.3171\/2017.10.JNS172236.","journal-title":"J Neurosurg"},{"key":"1503_CR56","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/jnnp-2018-319609","volume":"90","author":"C Mirian","year":"2019","unstructured":"Mirian C, Moller Pedersen M, Sabers A, Mathiesen T. Antiepileptic drugs as prophylaxis for de novo brain tumour-related epilepsy after craniotomy: a systematic review and meta-analysis of harm and benefits. J Neurol Neurosurg Psychiatry. 2019;90:599\u2013607. https:\/\/doi.org\/10.1136\/jnnp-2018-319609.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1503_CR57","doi-asserted-by":"publisher","first-page":"1543905","DOI":"10.3389\/fneur.2025.1543905","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Li H, Zhang B, Zhang J, Li C. Efficacy and safety of levetiracetam in preventing postoperative seizures in adult patients with brain tumors: a meta-analysis. Front Neurol. 2025;16:1543905. https:\/\/doi.org\/10.3389\/fneur.2025.1543905.","journal-title":"Front Neurol"},{"key":"1503_CR58","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/neuonc\/noq044","volume":"12","author":"GC Bobustuc","year":"2010","unstructured":"Bobustuc GC, Baker CH, Limaye A, et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol. 2010;12:917\u201327. https:\/\/doi.org\/10.1093\/neuonc\/noq044.","journal-title":"Neuro Oncol"},{"key":"1503_CR59","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11060-021-03940-2","volume":"156","author":"JS Chen","year":"2022","unstructured":"Chen JS, Clarke R, Haddad AF, et al. The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis. J Neurooncol. 2022;156:257\u201367. https:\/\/doi.org\/10.1007\/s11060-021-03940-2.","journal-title":"J Neurooncol"},{"key":"1503_CR60","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fonc.2012.00098","volume":"2","author":"M Nakada","year":"2012","unstructured":"Nakada M, Furuta T, Hayashi Y, Minamoto T, Hamada J. The strategy for enhancing temozolomide against malignant glioma. Front Oncol. 2012;2:98. https:\/\/doi.org\/10.3389\/fonc.2012.00098.","journal-title":"Front Oncol"},{"key":"1503_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-018-0626-8","author":"BMSS Scicchitano","year":"2018","unstructured":"Scicchitano BMSS, Proietti G, Lama G, Dobrowolny G, Catizone A, Binda E, Larocca LM, Sica G. Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell Int. 2018. https:\/\/doi.org\/10.1186\/s12935-018-0626-8.","journal-title":"Cancer Cell Int"},{"key":"1503_CR62","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1038\/cddis.2013.388","volume":"4","author":"CH Fan","year":"2013","unstructured":"Fan CH, Liu WL, Cao H, Wen C, Chen L, Jiang G. O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis. 2013;4:e876. https:\/\/doi.org\/10.1038\/cddis.2013.388.","journal-title":"Cell Death Dis"},{"key":"1503_CR63","doi-asserted-by":"publisher","first-page":"369","DOI":"10.4143\/crt.2024.355","volume":"57","author":"Y Lee","year":"2025","unstructured":"Lee Y, Lee E, Roh TH, Kim SH. Association between Levetiracetam Use and Survival in Patients with Glioblastoma: A Nationwide Population-Based Study. Cancer Res Treat. 2025;57:369\u201377. https:\/\/doi.org\/10.4143\/crt.2024.355.","journal-title":"Cancer Res Treat"},{"key":"1503_CR64","doi-asserted-by":"publisher","first-page":"10783","DOI":"10.1038\/s41598-020-67697-w","volume":"10","author":"TH Roh","year":"2020","unstructured":"Roh TH, Moon JH, Park HH, et al. Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy. Sci Rep. 2020;10:10783. https:\/\/doi.org\/10.1038\/s41598-020-67697-w.","journal-title":"Sci Rep"},{"key":"1503_CR65","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/01.wnl.0000324624.52935.46","volume":"71","author":"TA Milligan","year":"2008","unstructured":"Milligan TA, Hurwitz S, Bromfield EB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology. 2008;71:665\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000324624.52935.46.","journal-title":"Neurology"},{"key":"1503_CR66","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/nop\/npab059","volume":"9","author":"PB van der Meer","year":"2022","unstructured":"van der Meer PB, Dirven L, van den Bent MJ, et al. Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members. Neurooncol Pract. 2022;9:105\u201313. https:\/\/doi.org\/10.1093\/nop\/npab059.","journal-title":"Neurooncol Pract"},{"key":"1503_CR67","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1136\/jnnp-2014-308584","volume":"86","author":"T Iuchi","year":"2015","unstructured":"Iuchi T, Kuwabara K, Matsumoto M, Kawasaki K, Hasegawa Y, Sakaida T. Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomised study. J Neurol Neurosurg Psychiatry. 2015;86:1158\u201362. https:\/\/doi.org\/10.1136\/jnnp-2014-308584.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1503_CR68","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/neuonc\/nox209","volume":"20","author":"P Chinnaiyan","year":"2018","unstructured":"Chinnaiyan P, Won M, Wen PY, et al. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro Oncol. 2018;20:666\u201373. https:\/\/doi.org\/10.1093\/neuonc\/nox209.","journal-title":"Neuro Oncol"},{"key":"1503_CR69","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/neuonc\/noaa071","volume":"22","author":"NJ Ullrich","year":"2020","unstructured":"Ullrich NJ, Prabhu SP, Reddy AT, et al. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol. 2020;22:1527\u201335. https:\/\/doi.org\/10.1093\/neuonc\/noaa071.","journal-title":"Neuro Oncol"},{"key":"1503_CR70","unstructured":"Canadian Agency for Drugs and Technologies in Health. Everolimus (Afinitor). Common Drug Review. 2017 Sep. Date Access April 14, 2026 https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK525619\/"},{"key":"1503_CR71","unstructured":"Metayer JR. Marina: Undetectable Everolimus Level from Probable Drug\u2013Drug Interaction with Phenobarbital. J Hematol Oncol Pharm. 2018, 8."},{"key":"1503_CR72","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102017.","journal-title":"Cancer Treat Rev"},{"key":"1503_CR73","doi-asserted-by":"publisher","first-page":"175883592513178","DOI":"10.1177\/17588359251317846","volume":"17","author":"X Wu","year":"2025","unstructured":"Wu X, Lazris D, Wong R, Tykodi SS. Belzutifan for the treatment of renal cell carcinoma. Ther Adv Med Oncol. 2025;17:17588359251317846. https:\/\/doi.org\/10.1177\/17588359251317846.","journal-title":"Ther Adv Med Oncol"},{"key":"1503_CR74","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/neuonc\/noac234","volume":"25","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Nguyen CC, Zhang NT, et al. Neurological applications of belzutifan in von Hippel-Lindau disease. Neuro Oncol. 2023;25:827\u201338. https:\/\/doi.org\/10.1093\/neuonc\/noac234.","journal-title":"Neuro Oncol"},{"key":"1503_CR75","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3389\/fneur.2020.01036","volume":"11","author":"ZZ Xiao","year":"2020","unstructured":"Xiao ZZ, Wang ZF, Lan T, et al. Carmustine as a Supplementary Therapeutic Option for Glioblastoma: A Systematic Review and Meta-Analysis. Front Neurol. 2020;11:1036. https:\/\/doi.org\/10.3389\/fneur.2020.01036.","journal-title":"Front Neurol"},{"key":"1503_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.884158","volume":"13","author":"L Ricciardi","year":"2022","unstructured":"Ricciardi L, Manini I, Cesselli D, et al. Carmustine wafers implantation in patients with newly diagnosed high grade glioma: is it still an option? Front Neurol. 2022;13:884158. https:\/\/doi.org\/10.3389\/fneur.2022.884158.","journal-title":"Front Neurol"},{"key":"1503_CR77","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Carmustine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548307\/. Accessed 4\/14\/2026."},{"key":"1503_CR78","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1535-7511.2010.01374.x","volume":"10","author":"BE Gidal","year":"2010","unstructured":"Gidal BE. Pharmacokinetic interactions with antiepileptic drugs: always the bad actor or simply misunderstood? Epilepsy Curr. 2010;10:113\u20135. https:\/\/doi.org\/10.1111\/j.1535-7511.2010.01374.x.","journal-title":"Epilepsy Curr"},{"key":"1503_CR79","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01467-4","author":"A Markham","year":"2021","unstructured":"Markham A. Naxitamab: first approval. Drugs. 2021. https:\/\/doi.org\/10.1007\/s40265-021-01467-4.","journal-title":"Drugs"},{"key":"1503_CR80","doi-asserted-by":"publisher","first-page":"115797","DOI":"10.1016\/j.taap.2021.115797","volume":"434","author":"A Sorf","year":"2022","unstructured":"Sorf A, Vagiannis D, Ahmed F, Hofman J, Ceckova M. Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022;434:115797. https:\/\/doi.org\/10.1016\/j.taap.2021.115797.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1503_CR81","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Hansford JR, Garre ML, et al. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med. 2023;389:1108\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2303815.","journal-title":"N Engl J Med"},{"key":"1503_CR82","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.nec.2020.06.008","volume":"31","author":"MA Monsour","year":"2020","unstructured":"Monsour MA, Kelly PD, Chambless LB. Antiepileptic Drugs in the Management of Cerebral Metastases. Neurosurg Clin N Am. 2020;31:589\u2013601. https:\/\/doi.org\/10.1016\/j.nec.2020.06.008.","journal-title":"Neurosurg Clin N Am"},{"key":"1503_CR83","doi-asserted-by":"publisher","first-page":"CNS16","DOI":"10.2217\/cns-2017-0031","volume":"7","author":"VA Levin","year":"2018","unstructured":"Levin VA, Ictech SE, Hess KR. Clinical importance of eflornithine (alpha-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncol. 2018;7:CNS16. https:\/\/doi.org\/10.2217\/cns-2017-0031.","journal-title":"CNS Oncol"},{"key":"1503_CR84","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1200\/JCO.22.02875","volume":"42","author":"J Oesterheld","year":"2024","unstructured":"Oesterheld J, Ferguson W, Kraveka JM, et al. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons. J Clin Oncol. 2024;42:90\u2013102. https:\/\/doi.org\/10.1200\/JCO.22.02875.","journal-title":"J Clin Oncol"},{"key":"1503_CR85","doi-asserted-by":"crossref","unstructured":"Gerson SL, Caimi PF, William BM, Creger RJ. Chap. 57-Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies. In 2017.","DOI":"10.1016\/B978-0-323-35762-3.00057-3"},{"key":"1503_CR86","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11060-004-2338-2","volume":"72","author":"S Oberndorfer","year":"2005","unstructured":"Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol. 2005;72:255\u201360. https:\/\/doi.org\/10.1007\/s11060-004-2338-2.","journal-title":"J Neurooncol"},{"key":"1503_CR87","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/B978-0-12-809400-6.00024-X","volume-title":"Adverse Events and Oncotargeted Kinase Inhibitors","author":"G Tridente","year":"2017","unstructured":"Tridente G. Trametinib. In: Adverse Events and Oncotargeted Kinase Inhibitors. 2017. p. 531\u201359."},{"key":"1503_CR88","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Trametinib. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2018. Accessed 4\/14\/2026 https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548731\/"},{"key":"1503_CR89","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1200\/JCO.22.01000","volume":"41","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Geoerger B, Moertel C, et al. Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma. J Clin Oncol. 2023;41:664\u201374. https:\/\/doi.org\/10.1200\/JCO.22.01000.","journal-title":"J Clin Oncol"},{"key":"1503_CR90","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1158\/2767-9764.CRC-24-0451","volume":"5","author":"S Rastogi","year":"2025","unstructured":"Rastogi S, Perino S, Lal-Nag M, Wang Y, Blackman SC, Venetsanakos E. Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function Mutation. Cancer Res Commun. 2025;5:668\u201379. https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0451.","journal-title":"Cancer Res Commun"},{"key":"1503_CR91","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/17512433.2024.2418405","volume":"17","author":"T Zhang","year":"2024","unstructured":"Zhang T, Xu B, Tang F, He Z, Zhou J. Type II RAF inhibitor tovorafenib for the treatment of pediatric low-grade glioma. Expert Rev Clin Pharmacol. 2024;17:999\u20131008. https:\/\/doi.org\/10.1080\/17512433.2024.2418405.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1503_CR92","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41591-024-02910-1","volume":"30","author":"LB Kilburn","year":"2024","unstructured":"Kilburn LB, Khuong-Quang DA, Hansford JR, et al. Author Correction: The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2024;30:1500. https:\/\/doi.org\/10.1038\/s41591-024-02910-1.","journal-title":"Nat Med"},{"key":"1503_CR93","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3174\/ajnr.A2170","volume":"31","author":"JR Wesolowski","year":"2010","unstructured":"Wesolowski JR, Rajdev P, Mukherji SK. Temozolomide (Temodar). AJNR Am J Neuroradiol. 2010;31:1383\u20134. https:\/\/doi.org\/10.3174\/ajnr.A2170.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1503_CR94","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.3390\/curroncol30020147","volume":"30","author":"JL Jia","year":"2023","unstructured":"Jia JL, Alshamsan B, Ng TL. Temozolomide Chronotherapy in Glioma: A Systematic Review. Curr Oncol. 2023;30:1893\u2013902. https:\/\/doi.org\/10.3390\/curroncol30020147.","journal-title":"Curr Oncol"},{"key":"1503_CR95","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","volume":"77","author":"M Weller","year":"2011","unstructured":"Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma. Neurology. 2011;77:1156\u201364. https:\/\/doi.org\/10.1212\/WNL.0b013e31822f02e1.","journal-title":"Neurology"},{"key":"1503_CR96","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","volume":"92","author":"AV Krauze","year":"2015","unstructured":"Krauze AV, Myrehaug SD, Chang MG, et al. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. Int J Radiat Oncol Biol Phys. 2015;92:986\u201392. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.04.038.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1503_CR97","doi-asserted-by":"publisher","first-page":"7133","DOI":"10.1158\/1078-0432.CCR-07-0874","volume":"13","author":"ME Loghin","year":"2007","unstructured":"Loghin ME, Prados MD, Wen P, et al. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res. 2007;13:7133\u20138. https:\/\/doi.org\/10.1158\/1078.","journal-title":"Clin Cancer Res"},{"key":"1503_CR98","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s40265-024-02097-2","volume":"84","author":"YN Lamb","year":"2024","unstructured":"Lamb YN. Vorasidenib: First Approval. Drugs. 2024;84:1325\u201331. https:\/\/doi.org\/10.1007\/s40265-024-02097-2.","journal-title":"Drugs"},{"key":"1503_CR99","first-page":"92","volume":"42","author":"F Khaleghi","year":"2017","unstructured":"Khaleghi F, Nemec EC 2. Brivaracetam (Briviact): A Novel Adjunctive Therapy for Partial-Onset Seizures. P T. 2017;42:92\u20136.","journal-title":"P T"},{"key":"1503_CR100","unstructured":"BRIVIACT (brivaracetam). Package insert. UCB inc. 2021. https:\/\/www.fda.gov\/drugsatfda"},{"key":"1503_CR101","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.seizure.2015.07.004","volume":"31","author":"A Verrotti","year":"2015","unstructured":"Verrotti A, Prezioso G, Di Sabatino F, Franco V, Chiarelli F, Zaccara G. The adverse event profile of levetiracetam: A meta-analysis on children and adults. Seizure. 2015;31:49\u201355. https:\/\/doi.org\/10.1016\/j.seizure.2015.07.004.","journal-title":"Seizure"},{"key":"1503_CR102","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.seizure.2023.03.017","volume":"107","author":"A Celdran de Castro","year":"2023","unstructured":"Celdran de Castro A, Nascimento FA, Beltran-Corbellini A, et al. Levetiracetam, from broad-spectrum use to precision prescription: A narrative review and expert opinion. Seizure. 2023;107:121\u201331. https:\/\/doi.org\/10.1016\/j.seizure.2023.03.017.","journal-title":"Seizure"},{"key":"1503_CR103","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1528-1167.2012.03563.x","volume":"54","author":"KL Fuller","year":"2013","unstructured":"Fuller KL, Wang YY, Cook MJ, Murphy MA, D\u2019Souza WJ. Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: a prospective randomized study. Epilepsia. 2013;54:45\u201357. https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03563.x.","journal-title":"Epilepsia"},{"key":"1503_CR104","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/14740338.2020.1713089","volume":"19","author":"J Li","year":"2020","unstructured":"Li J, Sun M, Wang X. The adverse-effect profile of lacosamide. Expert Opin Drug Saf. 2020;19:131\u20138. https:\/\/doi.org\/10.1080\/14740338.2020.1713089.","journal-title":"Expert Opin Drug Saf"},{"key":"1503_CR105","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","volume":"110","author":"MA Rogawski","year":"2015","unstructured":"Rogawski MA, Tofighy A, White HS, Matagne A, Wolff C. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015;110:189\u2013205. https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.11.021.","journal-title":"Epilepsy Res"},{"key":"1503_CR106","unstructured":"VIMPAT (lacosamide). Package insert. UCB, inc. 2023. https:\/\/www.fda.gov\/drugsatfda"},{"key":"1503_CR107","unstructured":"LAMICTAL (lamotrigine). Package insert. GlaxoSmithKline LLC. 2025. https:\/\/www.fda.gov\/drugsatfda"},{"key":"1503_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076050","author":"B Costa","year":"2023","unstructured":"Costa B, Vale N. Understanding lamotrigine\u2019s role in the CNS and possible future evolution. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24076050.","journal-title":"Int J Mol Sci"},{"key":"1503_CR109","unstructured":"TOPAMAX (topiramate). Package insert. Janssen Pharmaceuticals, inc. 2026. https:\/\/www.fda.gov\/drugsatfda"},{"key":"1503_CR110","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.seizure.2022.03.024","volume":"98","author":"YF Bai","year":"2022","unstructured":"Bai YF, Zeng C, Jia M, Xiao B. Molecular mechanisms of topiramate and its clinical value in epilepsy. Seizure. 2022;98:51\u20136. https:\/\/doi.org\/10.1016\/j.seizure.2022.03.024.","journal-title":"Seizure"},{"key":"1503_CR111","doi-asserted-by":"publisher","first-page":"e200210","DOI":"10.1212\/CPJ.0000000000200210","volume":"14","author":"BE Gidal","year":"2024","unstructured":"Gidal BE, Resnick T, Smith MC, Wheless JW. Zonisamide: A Comprehensive, Updated Review for the Clinician. Neurol Clin Pract. 2024;14:e200210. https:\/\/doi.org\/10.1212\/CPJ.0000000000200210.","journal-title":"Neurol Clin Pract"},{"key":"1503_CR112","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1212\/wnl.57.10.1774","volume":"57","author":"E Faught","year":"2001","unstructured":"Faught E, Ayala R, Montouris GG, Leppik IE. Zonisamide 922 Trial G: Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001;57:1774\u20139. https:\/\/doi.org\/10.1212\/wnl.57.10.1774.","journal-title":"Neurology"},{"key":"1503_CR113","unstructured":"DEPAKENE (valproic acid). Package insert. AbbVie, inc. 2019. https:\/\/www.fda.gov\/drugsatfda"},{"key":"1503_CR114","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1056\/NEJM198003203021204","volume":"302","author":"J Koch-Weser","year":"1980","unstructured":"Koch-Weser J, Browne TR. Drug therapy: Valproic acid. N Engl J Med. 1980;302:661\u20136. https:\/\/doi.org\/10.1056\/NEJM198003203021204.","journal-title":"N Engl J Med"},{"key":"1503_CR115","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jsps.2022.12.001","volume":"31","author":"A Safdar","year":"2023","unstructured":"Safdar A, Ismail F. A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid. Saudi Pharm J. 2023;31:265\u201378. https:\/\/doi.org\/10.1016\/j.jsps.2022.12.001.","journal-title":"Saudi Pharm J"},{"key":"1503_CR116","unstructured":"Preuss CV, Randhawa G, Saadabadi A. Oxcarbazepine. StatPearls. Treasure Island (FL); 2026."},{"key":"1503_CR117","unstructured":"TRILEPTAL (oxcarbazepine). Package insert. Novartis Pharmaceuticals Corporation. 2025. https:\/\/www.fda.gov\/drugsatfda"},{"key":"1503_CR118","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40268-017-0197-5","volume":"17","author":"GL Galiana","year":"2017","unstructured":"Galiana GL, Gauthier AC, Mattson RH. Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures. Drugs R D. 2017;17:329\u201339. https:\/\/doi.org\/10.1007\/s40268-017-0197-5.","journal-title":"Drugs R D"},{"key":"1503_CR119","unstructured":"APTIOM (eslicarbazepine acetate). Package insert. Sunovion. 2019. https:\/\/www.fda.gov\/drugsatfda"},{"key":"1503_CR120","first-page":"683","volume":"41","author":"J Greenwood","year":"2016","unstructured":"Greenwood J, Valdes J. Perampanel (Fycompa): A Review of Clinical Efficacy and Safety in Epilepsy. P T. 2016;41:683\u201398.","journal-title":"P T"},{"key":"1503_CR121","unstructured":"FYCOMPA (perampanel). Package insert. Eisai, inc. 2019. https:\/\/www.fda.gov\/drugsatfda"},{"key":"1503_CR122","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","volume":"35","author":"R Roberti","year":"2021","unstructured":"Roberti R, De Caro C, Iannone LF, Zaccara G, Lattanzi S, Russo E. Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability. CNS Drugs. 2021;35:609\u201318. https:\/\/doi.org\/10.1007\/s40263-021-00819-8.","journal-title":"CNS Drugs"},{"key":"1503_CR123","unstructured":"XCOPRI (cenobamate). Package Insert. SK Life Science, inc. 2025. https:\/\/www.fda.gov\/drugsatfda"},{"key":"1503_CR124","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/epi.13267","volume":"57","author":"JM Nicolas","year":"2016","unstructured":"Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57:201\u20139. https:\/\/doi.org\/10.1111\/epi.13267.","journal-title":"Epilepsia"},{"key":"1503_CR125","doi-asserted-by":"publisher","first-page":"287","DOI":"10.25259\/SNI_495_2023","volume":"14","author":"K Kusakabe","year":"2023","unstructured":"Kusakabe K, Inoue A, Watanabe H, et al. Perioperative perampanel administration for early seizure prophylaxis in brain tumor patients. Surg Neurol Int. 2023;14:287. https:\/\/doi.org\/10.25259\/SNI_495_2023.","journal-title":"Surg Neurol Int"},{"key":"1503_CR126","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3892\/mco.2024.2740","volume":"20","author":"U Hino","year":"2024","unstructured":"Hino U, Tamura R, Kosugi K, et al. Optimizing perampanel monotherapy for surgically resected brain tumors. Mol Clin Oncol. 2024;20:42. https:\/\/doi.org\/10.3892\/mco.2024.2740.","journal-title":"Mol Clin Oncol"},{"key":"1503_CR127","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-24-1849","volume":"30","author":"S Tobochnik","year":"2024","unstructured":"Tobochnik S, Regan MS, Dorotan MKC, et al. Pilot Trial of Perampanel on Peritumoral Hyperexcitability in Newly Diagnosed High-grade Glioma. Clin Cancer Res. 2024;30:5365\u201373. 10.1158\/1078\u2009\u2013\u20090432.CCR-24-1849.","journal-title":"Clin Cancer Res"},{"key":"1503_CR128","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1586\/era.10.48","volume":"10","author":"CJ Vecht","year":"2010","unstructured":"Vecht CJ, Wilms EB. Seizures in low- and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther. 2010;10:663\u20139. https:\/\/doi.org\/10.1586\/era.10.48.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1503_CR129","doi-asserted-by":"publisher","first-page":"9","DOI":"10.14791\/btrt.2021.9.e7","volume":"9","author":"J Moon","year":"2021","unstructured":"Moon J, Kim MS, Kim YZ, et al. The Korean Society for Neuro-Oncology (KSNO) Guideline for Antiepileptic Drug Usage of Brain Tumor: Version 2021.1. Brain Tumor Res Treat. 2021;9:9\u201315. https:\/\/doi.org\/10.14791\/btrt.2021.9.e7.","journal-title":"Brain Tumor Res Treat"},{"issue":"Suppl 9","key":"1503_CR130","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/epi.12452","volume":"54","author":"E Perucca","year":"2013","unstructured":"Perucca E. Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia. 2013;54(Suppl 9):97\u2013104. https:\/\/doi.org\/10.1111\/epi.12452.","journal-title":"Epilepsia"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-026-01503-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-026-01503-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-026-01503-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:02:21Z","timestamp":1784577741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-026-01503-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":130,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1503"],"URL":"https:\/\/doi.org\/10.1007\/s11910-026-01503-4","relation":{},"ISSN":["1534-6293"],"issn-type":[{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"34"}}